Enchi Liu
Vice President, Head of Experimental Medicine Lundbeck
Seminars
Wednesday 3rd June 2026
Track B Chair
Thursday 4th June 2026
Track B Chair
Thursday 4th June 2026
Panel Discussion: Revitalizing the ALS Investment Landscape: Opportunities, Challenges, & the Path Forward
9:30 am
- What are the current barriers to investment in ALS therapeutics, and how can stakeholders address perceived scientific or clinical risks?
- Which emerging modalities or targets in ALS are attracting the most investor interest, and where do pharma companies see the greatest potential for collaboration?
- How can early-stage data, biomarkers, or patient-focused endpoints help de-risk ALS programs for investors and facilitate pharma partnerships?
- What lessons can be learned from past ALS investment successes and failures to guide more sustainable funding strategies?
- How can collaboration between VCs, corporate pharma, and patient advocacy groups accelerate both funding and development of ALS therapies?
Wednesday 3rd June 2026
Panel Discussion: Given Recent Failures, How Can We Tailor ALS Clinical Trials to Successfully Meet Regulatory Expectations
2:10 pm
- Leveraging innovative trial designs, such as adaptive, Bayesian, and platform models (e.g., MAGNET), alongside advanced outcome measures including PROs and digital endpoints to enhance trial success
- Defining clear, patient-relevant endpoints and integrating biomarkers to more effectively demonstrate clinical efficacy
- Navigating and aligning divergent regulatory expectations across agencies (e.g., FDA, EMA) to optimise trial design and approval pathways
- Identifying and mitigating late-stage risks by addressing common Phase 3 failure points and strengthening earlier-stage trial design, including adaptive Phase 2b approaches
Wednesday 3rd June 2026
Chair’s Opening Remarks
8:25 am
Thursday 4th June 2026
Chair’s Opening Remarks
9:25 am
Wednesday 3rd June 2026
Chair’s Closing Remarks
5:35 pm
Thursday 4th June 2026
Chair’s Closing Remarks
3:30 pm
